NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 190,476 Shares

NewAmsterdam Pharma (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 190,476 shares of the firm’s stock in a transaction that occurred on Tuesday, March 26th. The shares were sold at an average price of $21.50, for a total value of $4,095,234.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

NewAmsterdam Pharma Stock Performance

NAMS stock opened at $22.70 on Thursday. NewAmsterdam Pharma has a twelve month low of $5.63 and a twelve month high of $26.35. The business has a fifty day moving average of $21.52 and a 200-day moving average of $14.04.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Fcpm Iii Services B.V. acquired a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth $132,157,000. Bain Capital Life Sciences Investors LLC grew its stake in NewAmsterdam Pharma by 26.2% in the second quarter. Bain Capital Life Sciences Investors LLC now owns 10,473,913 shares of the company’s stock valued at $124,535,000 after acquiring an additional 2,173,913 shares during the period. RA Capital Management L.P. grew its stake in NewAmsterdam Pharma by 125.0% in the second quarter. RA Capital Management L.P. now owns 9,000,000 shares of the company’s stock valued at $107,010,000 after acquiring an additional 5,000,000 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $15,463,000. Finally, Parkman Healthcare Partners LLC boosted its position in shares of NewAmsterdam Pharma by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 300,750 shares of the company’s stock worth $3,359,000 after buying an additional 51,726 shares during the period. Institutional investors own 89.89% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on NAMS. Scotiabank began coverage on NewAmsterdam Pharma in a report on Thursday, March 14th. They set a “sector outperform” rating and a $35.00 price objective on the stock. Guggenheim began coverage on NewAmsterdam Pharma in a report on Thursday, January 18th. They set a “buy” rating and a $30.00 price objective on the stock. Royal Bank of Canada lifted their price objective on NewAmsterdam Pharma from $25.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, February 29th. Finally, Piper Sandler initiated coverage on NewAmsterdam Pharma in a research note on Tuesday, January 16th. They issued an “overweight” rating and a $37.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $31.00.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE).